Teva (TEVA) Investors Like CEO Succession Plan, Shares Move Higher
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA),shares are trading about 5 percent better Tuesday, following its CEO succession plans.
Late last Friday, Teva said CEO Shlomo Yanai will retire, and Bristol-Myers Squibb's Dr. Jeremy Levin will assume the role in May 2012.
For more color, click here.
Late last Friday, Teva said CEO Shlomo Yanai will retire, and Bristol-Myers Squibb's Dr. Jeremy Levin will assume the role in May 2012.
For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- TELA Bio cuts costs by $17M and replaces COO/CFO
- Rocket Companies names Alessio Sanfilippo as Redfin CEO
Create E-mail Alert Related Categories
Insiders' Blog, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
